Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.
Conditions
Interventions
G-CSF (filgrastim)
Cytosine arabinoside with G-CSF (filgrastim)
Locations
1
Poland
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch
Gliwice, Poland
Start Date
March 1, 2016
Primary Completion Date
March 1, 2017
Completion Date
April 1, 2017
Last Updated
March 30, 2016
NCT06667687
NCT05618925
NCT05623982
NCT03314974
NCT06014073
NCT04586478
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions